 SAN DIEGO and TORONTO, March 08, 2022 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Nasdaq: APTO; TSX: APS, a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update. 